DOCSLIB.ORG

Recombinant Tissue Plasminogen Activator (R-Tpa) Induces In-Vitro Human Neutrophil Migration Via Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recombinant Tissue Plasminogen Activator (R-Tpa) Induces In-Vitro Human Neutrophil Migration Via Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1) International Journal of Molecular Sciences Article Recombinant Tissue Plasminogen Activator (r-tPA) Induces In-Vitro Human Neutrophil Migration via Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1) 1,2, 2, 2 3 4 Luca Liberale y , Maria Bertolotto y, Silvia Minetti , Paola Contini , Daniela Verzola , Pietro Ameri 5,6, Giorgio Ghigliotti 5,6, Aldo Pende 5,7, Giovanni G. Camici 1, Federico Carbone 2,5 and Fabrizio Montecucco 2,5,* 1 Center for Molecular Cardiology, University of Zürich, Wagistrasse 12, 8952 Schlieren, Switzerland; [email protected] (L.L.); [email protected] (G.G.C.) 2 First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 Viale Benedetto XV, 16132 Genoa, Italy; [email protected] (M.B.); [email protected] (S.M.); [email protected] (F.C.) 3 Clinical Immunology, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy; [email protected] 4 Division of Nephrology, Dialysis and Transplantation, Department of Internal Medicine, University of Genoa, 6 Viale Benedetto XV, 16132 Genoa, Italy; [email protected] 5 IRCCS Ospedale Policlinico San Martino Genoa—Italian Cardiovascular Network, 10 Largo Benzi, 16132 Genoa, Italy; [email protected] (P.A.); [email protected] (G.G.); [email protected] (A.P.) 6 Laboratory of Cardiovascular Biology, IRCCS Ospedale Policlinico San Martino & Department of Internal Medicine, University of Genoa, 16126 Genoa, Italy 7 Clinic of Emergency Medicine, Department of Emergency Medicine, University of Genoa, 16126 Genoa, Italy * Correspondence: [email protected]; Tel.: +39-010-353-8694; Fax: +39-010-353-8686 These authors equally contributed as first author. y Received: 9 September 2020; Accepted: 22 September 2020; Published: 23 September 2020 Abstract: Thrombolysis is the gold standard treatment for acute ischemic stroke. Besides its fibrinolytic role, recombinant tissue plasminogen activator (r-tPA) holds several non-fibrinolytic functions. Here, we investigated the potential role of r-tPA on human primary neutrophil migration in vitro. By means of modified Boyden chamber migration assay and checkerboard analysis we showed a dose-dependent chemotactic effect of r-TPA with a maximum effect reached by 0.03 mg/mL (0.003–1 mg/mL). Pre-incubation with MAP kinases inhibitors allowed the identification of PI3K/Akt, but not ERK1/2 as the intracellular pathway mediating the observed effects. Furthermore, by means of real-time PCR, immunocytochemistry and cytofluorimetry we demonstrated that the r-tPA receptor low density lipoprotein receptor-related protein 1 (LRP-1) is synthetized and expressed by neutrophils in response to r-tPA and TNF-α. Inhibition of LRP-1 by receptor-associated protein (RAP), prevented r-tPA-mediated F-actin polymerization, migration and signal through Akt but not ERK1/2. Lastly, also neutrophil degranulation in response to r-tPA seems to be mediated by LRP-1 under adhesion conditions. In conclusion, we show that r-tPA induces neutrophil chemotaxis through LRP-1/Akt pathway. Blunting r-tPA-mediated neutrophil activation might be beneficial as an adjuvant therapy to thrombolysis in this setting. Keywords: tissue plasminogen activator; neutrophil; inflammation Int. J. Mol. Sci. 2020, 21, 7014; doi:10.3390/ijms21197014 www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2020, 21, 7014 2 of 14 1. Introduction Cerebro- and cardiovascular acute ischemic afflictions such as myocardial infarction and ischemic stroke benefit of early reperfusion to reduce organ damage. Together with interventional approaches, reperfusion strategies include the infusion of fibrinolytic agents such as recombinant tissue plasminogen activator (r-tPA). Currently, r-tPA represents the only medical therapy to improve outcomes in patients with acute ischemic stroke and its intravenous injection is recommended under specific conditions by international guidelines [1,2]. Yet, the late restoration of the blood flow in a previously ischemic tissue associates with a paradoxical exacerbation of inflammation and oxidative stress leading to cellular dysfunction and death, the so-called ischemia/reperfusion (I/R) injury [3]. Beside their important roles in host defence against infectious agents, neutrophils have been implicated in the pathogenesis of different conditions characterized by sterile inflammation such as I/R injury [4,5]. After blood flow re-establishment, circulating neutrophils are recruited early within the tissue and concur to its damage by different mechanisms including release of pro-inflammatory and pro-oxidant mediators such as interleukins and reactive oxygen species, degranulation of different proteases including matrix metalloproteases (MMPs), myeloperoxidase (MPO) and neutrophil elastase or formation of neutrophil extracellular traps [6]. Of interest, together with its direct action on vascular patency, r-tPA was also shown to contribute to I/R injury indirectly by inducing neutrophil degranulation both in-vitro and in-vivo [7]. Yet, the effect of r-tPA on neutrophil function remains only partially investigated, specifically the receptors and pathways involved in such process have not been fully identified. This information will be of utmost importance to counteract r-tPA-induced neutrophil activation potentially widening our interventional options in the setting of I/R injury and ischemic stroke. Accordingly, in this study, we investigated the role of r-tPA in human primary neutrophil migration. Furthermore, we characterized the membrane receptor and the intracellular pathways underlying the observed effect. 2. Results 2.1. r-tPA Induces Dose-Dependent Migration of Human Neutrophils Locomotory function of freshly isolated human neutrophils from healthy volunteers was tested in response to r-tPA employing the modified Boyden chamber assay with nitrocellulose filter. Concentrations of r-tPA herein employed are within the range observed in serum of patients undergoing thrombolysis [8]. Neutrophil migration toward different doses of r-tPA displayed the typical bell-shaped dose-response graphic of chemoattractants (Figure1A). The magnitude of neutrophil migration induced by 0.03 mg/mL r-tPA was similar to that generated by 1 nM chemokine (C-X-C motif) ligand 8 (CXCL8) (Figure1A), suggesting for r-tPA a powerful locomotion-inducing activity. To understand whether the migration was due to the induction of chemotaxis or to chemokinesis, we performed a checkerboard analysis with increasing concentrations of r-tPA above and below the filter (Figure1B). A directed migration vs. a gradient across the filter rather than random migration was observed indicating that r-tPA induces chemotaxis rather than random chemokinesis. Lastly, to investigate the signaling pathways involved in neutrophils migration towards r-tPA, we performed experiments with selective kinase inhibitors for PI3K and MEK1/2 (ERK1/2 activator). Figure1C shows that pre-incubation with 10 µM LY294002 (PI3K inhibitor) significantly reduced r-tPA-induced neutrophil migration. On the opposite, neutrophil pre-treatment with the MEK1/2 inhibitor U0126 had no effect on their migration (Figure1C). Int. J. Mol. Sci. 2020, 21, 7014 3 of 14 Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 3 of 14 Figure 1.FigureRecombinant 1. Recombinant tissue tissue plasminogen plasminogen activator (r-tPA) (r-tPA) induces induces dose-dependent dose-dependent migration migrationin in humanhuman neutrophils. neutrophils. ( A(A)) The graphic graphic represents represents the migration the migration assay of neutrophils assay of neutrophilstowards control towards control mediummedium (CTL), (CTL), r-tPA r-tPA (0.003 (0.003 mg/mL mg up/mL to 1 up mg/mL) to 1 mgor 1/ mL)nM CXCL8 or 1 nMas positive CXCL8 control. as positive Data are control. Data areexpressed as asmean mean of migration of migration distance distance (µm) ± (µ1 m)SEM 1in SEMthe nitrocellulose in the nitrocellulose assay, n = 5. assay, (B) n = 5. ± (B) CheckerboardCheckerboard analysis analysis showing showing that neutrophil neutrophil migration migration depends depends on a r-tPA on gradient a r-tPA across gradient the across filter. Untreated monocytes were seeded with increasing concentrations of r-tPA in the upper well, the filter. Untreated monocytes were seeded with increasing concentrations of r-tPA in the upper increasing concentrations of r-tPA were also added to the lower well. Data are expressed as mean of well, increasingchemotaxis concentrations index in the polycarbonate of r-tPA were assay, also n = added5. (C) Pre-treatment to the lower with well. PI3K DataInhibitor are reduces expressed as mean of chemotaxisneutrophils migration index in towards the polycarbonate r-tPA. Human assay,neutrophilsn = 5.were (C )pr Pre-treatmente-treated for 1 h with with PI3Kcontrol Inhibitor reduces neutrophilsmedium (CTL) migration or 10 µM towardsLY294002 r-tPA.(PI3K inhibitor, Human neutrophilsLY) or 10 µM wereU0126 pre-treated(MEK 1/2 inhibitor). for 1 h withThen control medium (CTL)their chemotactic or 10 µM function LY294002 was (PI3K tested inhibitor,towards 0.03 LY) mg/mL or 10 r-tPAµM U0126or 1nM (MEKCXCL8 1as/2 positive inhibitor). control. Then their Data are expressed as mean of migration distance (µm) ±1 SEM in the nitrocellulose assay, n = 6. chemotactic function was tested towards 0.03 mg/mL r-tPA or 1nM CXCL8 as positive control. Data are expressed as mean of migration distance (µm) 1 SEM in the nitrocellulose assay, n = 6. ± 2.2. Low-Density Lipoprotein Receptor-Related Protein-1 (LRP-1) Expression
Load more

Recommended publications
  • 1 Evidence for Gliadin Antibodies As Causative Agents in Schizophrenia
    1 Evidence for gliadin antibodies as causative agents in schizophrenia. C.J.Carter PolygenicPathways, 20 Upper Maze Hill, Saint-Leonard’s on Sea, East Sussex, TN37 0LG [email protected] Tel: 0044 (0)1424 422201 I have no fax Abstract Antibodies to gliadin, a component of gluten, have frequently been reported in schizophrenia patients, and in some cases remission has been noted following the instigation of a gluten free diet. Gliadin is a highly immunogenic protein, and B cell epitopes along its entire immunogenic length are homologous to the products of numerous proteins relevant to schizophrenia (p = 0.012 to 3e-25). These include members of the DISC1 interactome, of glutamate, dopamine and neuregulin signalling networks, and of pathways involved in plasticity, dendritic growth or myelination. Antibodies to gliadin are likely to cross react with these key proteins, as has already been observed with synapsin 1 and calreticulin. Gliadin may thus be a causative agent in schizophrenia, under certain genetic and immunological conditions, producing its effects via antibody mediated knockdown of multiple proteins relevant to the disease process. Because of such homology, an autoimmune response may be sustained by the human antigens that resemble gliadin itself, a scenario supported by many reports of immune activation both in the brain and in lymphocytes in schizophrenia. Gluten free diets and removal of such antibodies may be of therapeutic benefit in certain cases of schizophrenia. 2 Introduction A number of studies from China, Norway, and the USA have reported the presence of gliadin antibodies in schizophrenia 1-5. Gliadin is a component of gluten, intolerance to which is implicated in coeliac disease 6.
    [Show full text]
  • Clinical Protocol
    CLINICAL PROTOCOL Subject: Page Protocol # EMERGENT TREATMENT OF PATIENTS WITH BLEEDING AND 1 of 4 NMH CCP 07.0024 CLOTTING EMERGENCIES WHO ARE TAKING NOVEL ORAL ANTICOAGULANTS Version: 1.0 Title: Revision of: Effective Date: EMERGENT TREATMENT OF PATIENTS WITH BLEEDING AND NEW 04/29/2013 CLOTTING EMERGENCIES WHO ARE TAKING NOVEL ORAL Removal Date: ANTICOAGULANT APIXABAN (ELIQUIS) I. PURPOSE: To standardize management of patients with bleeding and clotting emergencies who are taking novel oral anticoagulants (NOACs). This protocol covers emergent reversal and ischemic stroke in patients on apixaban (Eliquis) therapy. II. CLINICAL PROTOCOL: A. The NOAC apixaban (Eliquis) is FDA approved for stroke prevention in patients with atrial fibrillation. This agent presents clinicians with several challenges because there are no specific antidotes, and no readily available quantitative assay to determine the degree of anticoagulation in a patient on this therapy. B. Patients taking this agent are likely to present to the hospital with; 1. life-threatening bleeding (e.g., intracerebral hemorrhage or GI bleeding), or a need for an emergent invasive procedure (surgery, cardiac Catherization) 2. acute ischemic stroke. The administration of tissue plasminogen activator (IV tPA) in the setting of NOAC use is potentially dangerous. C. There are no accepted evidence-based guidelines for managing these situations. This protocol is a consensus of clinicians from stroke, neurology, neurosurgery, hematology, neurocritical care, laboratory medicine, cardiology, and pharmacy. III. REVERSAL PROTOCOL FOR PATIENTS WITH SEVERE/LIFE-THREATENING BLEEDING TAKING APIXABAN (ELIQUIS) A. Inclusion criteria: 1. Patient has taken any dose of apixaban within last 48 hours. a. If time of last dose is unknown, but patient is suspected of having taken apixaban in last 48 hours, and PT is abnormal and 2.
    [Show full text]
  • The Central Role of Fibrinolytic Response in COVID-19—A Hematologist’S Perspective
    International Journal of Molecular Sciences Review The Central Role of Fibrinolytic Response in COVID-19—A Hematologist’s Perspective Hau C. Kwaan 1,* and Paul F. Lindholm 2 1 Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA 2 Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; [email protected] * Correspondence: [email protected] Abstract: The novel coronavirus disease (COVID-19) has many characteristics common to those in two other coronavirus acute respiratory diseases, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). They are all highly contagious and have severe pulmonary complications. Clinically, patients with COVID-19 run a rapidly progressive course of an acute respiratory tract infection with fever, sore throat, cough, headache and fatigue, complicated by severe pneumonia often leading to acute respiratory distress syndrome (ARDS). The infection also involves other organs throughout the body. In all three viral illnesses, the fibrinolytic system plays an active role in each phase of the pathogenesis. During transmission, the renin-aldosterone- angiotensin-system (RAAS) is involved with the spike protein of SARS-CoV-2, attaching to its natural receptor angiotensin-converting enzyme 2 (ACE 2) in host cells. Both tissue plasminogen activator (tPA) and plasminogen activator inhibitor 1 (PAI-1) are closely linked to the RAAS. In lesions in the lung, kidney and other organs, the two plasminogen activators urokinase-type plasminogen activator (uPA) and tissue plasminogen activator (tPA), along with their inhibitor, plasminogen activator 1 (PAI-1), are involved. The altered fibrinolytic balance enables the development of a hypercoagulable Citation: Kwaan, H.C.; Lindholm, state.
    [Show full text]
  • In Sickness and in Health: the Immunological Roles of the Lymphatic System
    International Journal of Molecular Sciences Review In Sickness and in Health: The Immunological Roles of the Lymphatic System Louise A. Johnson MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK; [email protected] Abstract: The lymphatic system plays crucial roles in immunity far beyond those of simply providing conduits for leukocytes and antigens in lymph fluid. Endothelial cells within this vasculature are dis- tinct and highly specialized to perform roles based upon their location. Afferent lymphatic capillaries have unique intercellular junctions for efficient uptake of fluid and macromolecules, while expressing chemotactic and adhesion molecules that permit selective trafficking of specific immune cell subsets. Moreover, in response to events within peripheral tissue such as inflammation or infection, soluble factors from lymphatic endothelial cells exert “remote control” to modulate leukocyte migration across high endothelial venules from the blood to lymph nodes draining the tissue. These immune hubs are highly organized and perfectly arrayed to survey antigens from peripheral tissue while optimizing encounters between antigen-presenting cells and cognate lymphocytes. Furthermore, subsets of lymphatic endothelial cells exhibit differences in gene expression relating to specific func- tions and locality within the lymph node, facilitating both innate and acquired immune responses through antigen presentation, lymph node remodeling and regulation of leukocyte entry and exit. This review details the immune cell subsets in afferent and efferent lymph, and explores the mech- anisms by which endothelial cells of the lymphatic system regulate such trafficking, for immune surveillance and tolerance during steady-state conditions, and in response to infection, acute and Citation: Johnson, L.A.
    [Show full text]
  • Elastase-Induced Pulmonary Emphysema: Insights from Experimental Models
    “main” — 2011/10/13 — 23:40 — page 1385 — #1 Anais da Academia Brasileira de Ciências (2011) 83(4): 1385-1395 (Annals of the Brazilian Academy of Sciences) Printed version ISSN 0001-3765 / Online version ISSN 1678-2690 www.scielo.br/aabc Elastase-induced pulmonary emphysema: insights from experimental models MARIANA A. ANTUNES and PATRICIA R.M. ROCCO Laboratório de Investigação Pulmonar, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde, Av. Carlos Chagas Filho, s/n, Cidade Universitária, Ilha do Fundão, 21941-902 Rio de Janeiro, RJ, Brasil Manuscript received on November 8, 2010; accepted for publication on May 19, 2011 ABSTRACT Several distinct stimuli can be used to reproduce histological and functional features of human emphysema, a lead- ing cause of disability and death. Since cigarette smoke is the main cause of emphysema in humans, experimental researches have attempted to reproduce this situation. However, this is an expensive and cumbersome method of em- physema induction, and simpler, more efficacious alternatives have been sought. Among these approaches, elastolytic enzymes have been widely used to reproduce some characteristics of human cigarette smoke-induced disease, such as: augmentation of airspaces, inflammatory cell influx into the lungs, and systemic inflammation. Nevertheless, theuse of elastase-induced emphysema models is still controversial, since the disease pathways involved in elastase induction may differ from those occurring in smoke-induced emphysema. This indicates that the choice of an emphysema model may impact the results of new therapies or drugs being tested. The aim of this review is to compare the mechanisms of disease induction in smoke and elastase emphysema models, to describe the differences among various elastase models, and to establish the advantages and disadvantages of elastase-induced emphysema models.
    [Show full text]
  • IL-33 Is Processed Into Mature Bioactive Forms by Neutrophil Elastase and Cathepsin G
    IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G Emma Lefrançais, Stephane Roga, Violette Gautier, Anne Gonzalez-de-Peredo, Bernard Monsarrat, Jean-Philippe Girard1,2, and Corinne Cayrol1,2 Centre National de la Recherche Scientifique, Institut de Pharmacologie et de Biologie Structurale, F-31077 Toulouse, France; Université de Toulouse, Université Paul Sabatier, Institut de Pharmacologie et de Biologie Structurale, F-31077 Toulouse, France Edited* by Charles A. Dinarello, University of Colorado Denver, Aurora, CO, and approved December 19, 2011 (received for review October 3, 2011) Interleukin-33 (IL-33) (NF-HEV) is a chromatin-associated nuclear activity (4). However, we (23) and others (24–26) demonstrated cytokine from the IL-1 family, which has been linked to important that full-length IL-33 is biologically active and that processing of diseases, including asthma, rheumatoid arthritis, ulcerative colitis, IL-33 by caspases results in its inactivation, rather than its activa- and cardiovascular diseases. IL-33 signals through the ST2 receptor tion. Further analyses revealed that IL-33 is constitutively and drives cytokine production in type 2 innate lymphoid cells (ILCs) expressed to high levels in the nuclei of endothelial and epithelial (natural helper cells, nuocytes), T-helper (Th)2 lymphocytes, mast cells in vivo (27) and that it can be released in the extracellular cells, basophils, eosinophils, invariant natural killer T (iNKT), and space after cellular damage (23, 24). IL-33 was, thus, proposed (23, natural killer (NK) cells. We and others recently reported that, unlike 24, 27) to function as an endogenous danger signal or alarmin, IL-1β and IL-18, full-length IL-33 is biologically active independently similar to IL-1α and high-mobility group box 1 protein (HMGB1) of caspase-1 cleavage and that processing by caspases results in IL-33 (28–32), to alert cells of the innate immune system of tissue inactivation.
    [Show full text]
  • ACTIVASE (Alteplase) for Injection, for Intravenous Use Initial U.S
    Application 103172 This document contains: Label for ACTIVASE [Supplement 5203, Action Date 02/13/2015] Also available: Label for CATHFLO ACTIVASE [Supplement 5071, Action Date 01/04/2005] HIGHLIGHTS OF PRESCRIBING INFORMATION Acute Ischemic Stroke These highlights do not include all the information needed to use • Current intracranial hemorrhage. (4.1) ACTIVASE safely and effectively. See full prescribing information for • Subarachnoid hemorrhage. (4.1) ACTIVASE. Acute Myocardial Infarction or Pulmonary Embolism • History of recent stroke. (4.2) ACTIVASE (alteplase) for injection, for intravenous use Initial U.S. Approval: 1987 -----------------------WARNINGS AND PRECAUTIONS-----------------------­ • Increases the risk of bleeding. Avoid intramuscular injections. Monitor for ---------------------------INDICATIONS AND USAGE--------------------------­ bleeding. If serious bleeding occurs, discontinue Activase. (5.1) Activase is a tissue plasminogen activator (tPA) indicated for the treatment of • Monitor patients during and for several hours after infusion for orolingual • Acute Ischemic Stroke (AIS). (1.1) angioedema. If angioedema develops, discontinue Activase. (5.2) • Acute Myocardial Infarction (AMI) to reduce mortality and incidence of • Cholesterol embolism has been reported rarely in patients treated with heart failure. (1.2) thrombolytic agents. (5.3) Limitation of Use in AMI: the risk of stroke may be greater than the benefit • Consider the risk of reembolization from the lysis of underlying deep in patients at low risk of death
    [Show full text]
  • A First in Class Treatment for Thrombosis Prevention. a Phase I
    Journal of Cardiology and Vascular Medicine Research Open Access A First in Class Treatment for Thrombosis Prevention. A Phase I study with CS1, a New Controlled Release Formulation of Sodium Valproate 1,2* 2 3 2 1,2 Niklas Bergh , Jan-Peter Idström , Henri Hansson , Jonas Faijerson-Säljö , Björn Dahlöf 1Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden 2 Cereno Scientific AB, Gothenburg, Sweden 3 Galenica AB, Malmö, Sweden *Corresponding author: Niklas Bergh, The Wallenberg Laboratory for Cardiovascular Research Sahlgrenska University Hospi- tal Bruna Stråket 16, 413 45 Göteborg, Tel: +46 31 3421000; E-Mail: [email protected] Received Date: June 11, 2019 Accepted Date: July 25, 2019 Published Date: July 27, 2019 Citation: Niklas Bergh (2019) A First in Class Treatment for Thrombosis Prevention? A Phase I Study With Cs1, a New Con- trolled Release Formulation of Sodium Valproate. J Cardio Vasc Med 5: 1-12. Abstract Several lines of evidence indicate that improving fibrinolysis by valproic acid may be a fruitful strategy for throm- bosis prevention. This study investigated the safety, pharmacokinetics, and effect on biomarkers for thrombosis of CS1, a new advanced controlled release formulation of sodium valproate designed to produce optimum valproic acid concen- trations during the early morning hours, when concentrations of plasminogen activator inhibitor (PAI)-1 and the risk of thrombotic events is highest. Healthy volunteers (n=17) aged 40-65 years were randomized to receive single doses of one of three formulations of CS1 (FI, FII, and FIII). The CS1 FII formulation showed the most favorable pharmacokinetics and was chosen for multiple dosing.
    [Show full text]
  • Enzymes for Cell Dissociation and Lysis
    Issue 2, 2006 FOR LIFE SCIENCE RESEARCH DETACHMENT OF CULTURED CELLS LYSIS AND PROTOPLAST PREPARATION OF: Yeast Bacteria Plant Cells PERMEABILIZATION OF MAMMALIAN CELLS MITOCHONDRIA ISOLATION Schematic representation of plant and bacterial cell wall structure. Foreground: Plant cell wall structure Background: Bacterial cell wall structure Enzymes for Cell Dissociation and Lysis sigma-aldrich.com The Sigma Aldrich Web site offers several new tools to help fuel your metabolomics and nutrition research FOR LIFE SCIENCE RESEARCH Issue 2, 2006 Sigma-Aldrich Corporation 3050 Spruce Avenue St. Louis, MO 63103 Table of Contents The new Metabolomics Resource Center at: Enzymes for Cell Dissociation and Lysis sigma-aldrich.com/metpath Sigma-Aldrich is proud of our continuing alliance with the Enzymes for Cell Detachment International Union of Biochemistry and Molecular Biology. Together and Tissue Dissociation Collagenase ..........................................................1 we produce, animate and publish the Nicholson Metabolic Pathway Hyaluronidase ...................................................... 7 Charts, created and continually updated by Dr. Donald Nicholson. DNase ................................................................. 8 These classic resources can be downloaded from the Sigma-Aldrich Elastase ............................................................... 9 Web site as PDF or GIF files at no charge. This site also features our Papain ................................................................10 Protease Type XIV
    [Show full text]
  • CELA1 Antibody (N-Term) Blocking Peptide Synthetic Peptide Catalog # Bp17787a
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 CELA1 Antibody (N-term) Blocking Peptide Synthetic peptide Catalog # BP17787a Specification CELA1 Antibody (N-term) Blocking Peptide CELA1 Antibody (N-term) Blocking Peptide - - Background Product Information Elastases form a subfamily of serine proteases Primary Accession Q9UNI1 thathydrolyze many proteins in addition to elastin. Humans have sixelastase genes which encode the structurally similar proteinselastase CELA1 Antibody (N-term) Blocking Peptide - Additional Information 1, 2, 2A, 2B, 3A, and 3B. Unlike other elastases,pancreatic elastase 1 is not expressed in the pancreas. To date,elastase 1 Gene ID 1990 expression has only been detected in skin keratinocytes.Clinical literature that describes Other Names human elastase 1 activity in thepancreas or Chymotrypsin-like elastase family member fecal material is actually referring 1, Elastase-1, Pancreatic elastase 1, CELA1, tochymotrypsin-like elastase family, member ELA1 3B. Format Peptides are lyophilized in a solid powder CELA1 Antibody (N-term) Blocking Peptide format. Peptides can be reconstituted in - References solution using the appropriate buffer as needed. Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Rose, J.E., et al. Mol. Storage Med. 16 (7-8), 247-253 (2010) :Roberts, K.E., Maintain refrigerated at 2-8°C for up to 6 et al. Gastroenterology months. For long term storage store at 139(1):130-139(2010)Talmud, P.J., et al. Am. J. -20°C. Hum. Genet. 85(5):628-642(2009)Talas, U., et al. J. Invest. Dermatol. 114(1):165-170(2000) Precautions This product is for research use only.
    [Show full text]
  • Tumor-Associated and Microbial Proteases Compromise Host Igg Effector Functions by a Single Cleavage Proximal to the Hinge
    Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge Randall J. Brezski1, Omid Vafa, Diane Petrone, Susan H. Tam, Gordon Powers, Mary H. Ryan, Jennifer L. Luongo, Allison Oberholtzer, David M. Knight, and Robert E. Jordan1 Biologics Research, Centocor R&D Inc., Radnor, PA 19087 Edited by Barry S. Coller, The Rockefeller University, New York, NY, and approved August 31, 2009 (received for review April 15, 2009) The successful elimination of pathogenic cells and microorganisms responsible for binding the MHC-class I related receptor, the by the humoral immune system relies on effective interactions neonatal Fc receptor (FcRn) that mediates the serum half-life of between host immunoglobulins and Fc␥ receptors on effector cells, circulating IgGs (14–16), are located in the area between the CH2 in addition to the complement system. Essential Ig motifs that and CH3 regions of the Fc (17–19). direct those interactions reside within the conserved IgG lower Several groups previously documented that certain proteases hinge/CH2 interface. We noted that a group of tumor-related and associated with inflammation, tumor invasion, metastasis, and microbial proteases cleaved human IgG1s in that region, and the bacterial infections have the ability to cleave IgGs (20, 21). Several ‘‘nick’’ of just one of the heavy chains profoundly inhibited IgG1 proteases preferentially cleave IgGs in the lower hinge, including effector functions. We focused on IgG1 monoclonal antibodies the matrix metalloproteinases (MMPs) stromelysin-1 (MMP-3), (mAbs) since IgG1 is the most abundant human subclass and metalloelastase (MMP-12) (both cleave between P232 and E233), demonstrates robust Fc-mediated effector functions.
    [Show full text]
  • Original Article Endogenous Risk Factors for Deep-Vein Thrombosis in Patients with Acute Spinal Cord Injuries
    Spinal Cord (2007) 45, 627–631 & 2007 International Spinal Cord Society All rights reserved 1362-4393/07 $30.00 www.nature.com/sc Original Article Endogenous risk factors for deep-vein thrombosis in patients with acute spinal cord injuries S Aito*,1, R Abbate2, R Marcucci2 and E Cominelli1 1Spinal Unit, Careggi University Hospital, Florence, Italy; 2Medical division, coagulation disease, Careggi University Hospital, Florence, Italy Study design: Case–control study. Aim of the study: Investigate the presence of additional endogenous risk factors of deep-vein thrombosis (DVT). Setting: Regional Spinal Unit of Florence, Italy. Methods: A total of 43 patients with spinal lesion and a history of DVT during the acute stage of their neurological impairment (Group A) were comprehensively evaluated and the blood concentrations of the following risk factors, that are presumably associated with DVT, were determined: antithrombin III (ATIII), protein C (PC), protein S (PS), factor V Leiden, gene 200210A polymorphism, homocysteine (Hcy), inhibitor of plasminogen activator-1 (PAI-1) and lipoprotein A (LpA). The control group (Group B) consisted of 46 patients matched to Group A for sex, age, neurological status and prophylactic treatment during the acute stage, with no history of DVT. Statistical analysis was performed using the Mann–Whitney and Fisher’s exact tests. Results: Of the individuals in GroupA, 14% had no risk factor and 86% had at least one; however, in GroupB 54% had no endogenous risk factors and 46% had at least one. None of the individuals in either grouphad a deficit in their coagulation inhibitors (ATIII, PC and PS), and the LpA level was equivalent in the two groups.
    [Show full text]